By Aubrey Harris, American Spectator - Earlier this month, some Senate members attended a closed-door briefing with FDA Commissioner Marty Makary. One of the topics of conversation? The abortion pill, mifepristone... Apparently, the briefing didn’t go super well. The FDA is in the process of doing a safety review of mifepristone, but according to Sen. Josh Hawley (R-Mo.), Makary couldn’t give a timeline on that review... It should be noted that the safety review is rather important. Last year, the Ethics and Public Policy Center used insurance claims to determine that “the rate of life-threatening complications due to mifepristone is at least 22 times higher than what the FDA … suggest[s].”